During treatment with lomitapide in the pivotal phase 3 and extension trials, circulating levels of CK‐18 and CK‐18 fragments were measured as biomarkers of hepatic inflammation and indicators of non‐alcoholic steatohepatitis (NASH). This evidence concerns the gene KRT18 and metabolic dysfunction-associated steatohepatitis.